Kieran J Rothnie1,2, Hana Müllerová3, Liam Smeeth2, Jennifer K Quint1,2. 1. 1 Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom. 2. 2 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom; and. 3. 3 Respiratory Epidemiology, GlaxoSmithKline R&D, Uxbridge, United Kingdom.
Abstract
RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are important adverse events in the natural history of chronic obstructive pulmonary disease (COPD). OBJECTIVES: To investigate the natural history of AECOPDs over 10 years of follow-up. METHODS: We identified 99,574 patients with COPD from January 1, 2004, to March 31, 2015, from the UK Clinical Practice Research Datalink. We defined moderate AECOPDs as those managed outside hospital and severe as those requiring hospitalization. During the baseline period (first year of follow-up), patients were grouped according to the number and severity of AECOPDs and then followed for a maximum of 10 years (mean, 4.9 yr). We investigated the effect of baseline AECOPD number and severity on risk of further events and death. MEASUREMENTS AND MAIN RESULTS: Around one-quarter of the patients with COPD did not exacerbate during follow-up. Compared with no AECOPDs in the baseline period, AECOPD number predicted the future long-term rate of AECOPDs in a graduated fashion, ranging from hazard ratio (HR) of 1.71 (1.66-1.77) for one event to HR of 3.41 (3.27-3.56) for five or more events. Two or more moderate AECOPDs were also associated with an increased risk of death in a graduated fashion, ranging from HR of 1.10 (1.03-1.18) for two moderate AECOPDs to HR of 1.57 (1.45-1.70) for five or more moderate AECOPDs, compared with those with no AECOPDs at baseline. Severe AECOPDs were associated with an even higher risk of death (HR, 1.79; 1.65-1.94). CONCLUSIONS: A large proportion of patients with COPD do not exacerbate over a maximum 10 years of follow-up. AECOPD frequency in a single year predicts long-term AECOPD rate. Increasing frequency and severity of AECOPDs is associated with risk of death and highlights the importance of preventing AECOPDs.
RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are important adverse events in the natural history of chronic obstructive pulmonary disease (COPD). OBJECTIVES: To investigate the natural history of AECOPDs over 10 years of follow-up. METHODS: We identified 99,574 patients with COPD from January 1, 2004, to March 31, 2015, from the UK Clinical Practice Research Datalink. We defined moderate AECOPDs as those managed outside hospital and severe as those requiring hospitalization. During the baseline period (first year of follow-up), patients were grouped according to the number and severity of AECOPDs and then followed for a maximum of 10 years (mean, 4.9 yr). We investigated the effect of baseline AECOPD number and severity on risk of further events and death. MEASUREMENTS AND MAIN RESULTS: Around one-quarter of the patients with COPD did not exacerbate during follow-up. Compared with no AECOPDs in the baseline period, AECOPD number predicted the future long-term rate of AECOPDs in a graduated fashion, ranging from hazard ratio (HR) of 1.71 (1.66-1.77) for one event to HR of 3.41 (3.27-3.56) for five or more events. Two or more moderate AECOPDs were also associated with an increased risk of death in a graduated fashion, ranging from HR of 1.10 (1.03-1.18) for two moderate AECOPDs to HR of 1.57 (1.45-1.70) for five or more moderate AECOPDs, compared with those with no AECOPDs at baseline. Severe AECOPDs were associated with an even higher risk of death (HR, 1.79; 1.65-1.94). CONCLUSIONS: A large proportion of patients with COPD do not exacerbate over a maximum 10 years of follow-up. AECOPD frequency in a single year predicts long-term AECOPD rate. Increasing frequency and severity of AECOPDs is associated with risk of death and highlights the importance of preventing AECOPDs.
Authors: John R Hurst; Gavin C Donaldson; Jennifer K Quint; James J P Goldring; Ramin Baghai-Ravary; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2008-12-12 Impact factor: 21.405
Authors: Bartolome R Celli; Nicholas Locantore; Julie Yates; Ruth Tal-Singer; Bruce E Miller; Per Bakke; Peter Calverley; Harvey Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; Annelyse Duvoix; William MacNee; Stephen Rennard; Edwin Silverman; Jørgen Vestbo; Emiel Wouters; Alvar Agustí Journal: Am J Respir Crit Care Med Date: 2012-03-15 Impact factor: 21.405
Authors: Hana Müllerova; Diego J Maselli; Nicholas Locantore; Jørgen Vestbo; John R Hurst; Jadwiga A Wedzicha; Per Bakke; Alvar Agusti; Antonio Anzueto Journal: Chest Date: 2015-04 Impact factor: 9.410
Authors: David M G Halpin; Marc Decramer; Bartolome Celli; Steven Kesten; Dacheng Liu; Donald P Tashkin Journal: Int J Chron Obstruct Pulmon Dis Date: 2012-09-21
Authors: Sigrun Alba Johannesdottir Schmidt; Martin Berg Johansen; Morten Olsen; Xiao Xu; Joseph M Parker; Nestor A Molfino; Timothy L Lash; Henrik Toft Sørensen; Christian Fynbo Christiansen Journal: BMJ Open Date: 2014-12-19 Impact factor: 2.692
Authors: Wassim W Labaki; Lucas M Kimmig; Gökhan M Mutlu; MeiLan K Han; Surya P Bhatt Journal: Am J Respir Crit Care Med Date: 2019-06-15 Impact factor: 21.405
Authors: Kirsty Rhodes; Martin Jenkins; Enrico de Nigris; Magnus Aurivillius; Mario Ouwens Journal: BMC Med Res Methodol Date: 2022-05-25 Impact factor: 4.612
Authors: Maria Pikoula; Jennifer Kathleen Quint; Francis Nissen; Harry Hemingway; Liam Smeeth; Spiros Denaxas Journal: BMC Med Inform Decis Mak Date: 2019-04-18 Impact factor: 2.796
Authors: Claus F Vogelmeier; Konstantinos Kostikas; Juanzhi Fang; Hengfeng Tian; Bethan Jones; Christopher Ll Morgan; Robert Fogel; Florian S Gutzwiller; Hui Cao Journal: Respir Res Date: 2019-08-07
Authors: Dirk-Jan Slebos; Bruno Degano; Arschang Valipour; Pallav L Shah; Gaetan Deslée; Frank C Sciurba Journal: BMC Pulm Med Date: 2020-02-13 Impact factor: 3.317
Authors: David B Price; Jaco Voorham; Guy Brusselle; Andreas Clemens; Konstantinos Kostikas; Jeffrey W Stephens; Hye Yun Park; Nicolas Roche; Robert Fogel Journal: NPJ Prim Care Respir Med Date: 2019-10-28 Impact factor: 2.871